Skip to main content
Premium Trial:

Request an Annual Quote

Glaxo Wellcome, NeXstar Announce Collaboration


BOULDER, Colo.--NeXstar Pharmaceuticals here announced a three-part collaboration with Glaxo Wellcome. The agreement grants Glaxo nonexclusive use of NeXstar's proprietary Selex drug discovery process, a combinatorial chemistry technology, as a research tool for target validation in Glaxo's functional genomics program. Additionally, NeXstar will receive exclusive rights to develop and commercialize a liposomal formulation of Glaxo's proprietary topoisomerase I inhibitor, a compound that has completed phase two clinical trials for the treatment of various cancers in its nonliposomal form. Glaxo will also make a $10 million equity investment in NeXstar, purchasing 962,117 shares of NeXstar common stock for $10.39 per share.

NeXstar CEO Patrick Mahaffy said Glaxo's interest in using the Selex technology for target validation "highlights the potential for aptamers to significantly speed up and improve drug discovery and development programs." Mahaffy said his company is also enthusiastic about the opportunity to develop liposomal lurtotecan.

Filed under

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.